AMZ001

Small molecule

AAmzell

AMZ001 is one of 25 small molecule programs targeting Osteoarthritis. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

OsteoarthritisActive, not recruiting

OsteoarthritisPhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

778 competitors in Osteoarthritis

#DrugCompanyPhaseTrials

Toradol

Roche

Preclinical

1 2

Cataflam

Platelet Rich Plasma

25 4

Voltaren

CCerimon Pharmaceuticals

Preclinical

4 5

Enbrel

IImmunex

Preclinical

2 6

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

1 7

Protonix

WWyeth-Lederle Vaccines

Preclinical

1 8

Catapres

Boehringer Ingelheim

Preclinical

1 9

Paracetamol

GSK

Preclinical

4 10

Naproxen Sodium

Bayer

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Osteoarthritis2 trials

A Study to Evaluate Efficacy and Safety of AMZ001 for the Treatment of Knee Osteoarthritis Symptoms

Active, not recruiting·AAmzell·Phase 3·NCT06693648·540 enrolled

AMZ001 for the Treatment of Knee Osteoarthritis Symptoms

Completed·AAmzell·Phase 2/3·NCT03691844·444 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for AMZ001. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AMZ001 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AMZ001. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Amzell company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: AAmzell

AMZ001

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Osteoarthritis2 trials

References

Drug Info

Quick Facts

Related News